Canopy Gwth (NASDAQ:CGC) Stock

Canopy Gwth

Canopy Growth

Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Doja, 7ACRES, Tweed, and Deep Space. Its non-THC products include skincare products under Martha Stewart CBD and Storz & Bickel vaporizers. Canopy growth merged its US assets into a separately operated holding company, Canopy USA, which will not be consolidated into the Canadian company's financials.

STORZ & BICKEL

Cannabis

Exclusives

Tech

Interview

STORZ &amp; BICKEL is redefining vaporization with medical-grade precision. From the Volcano to the VENTY, Jürgen Bickel shares what&#39;s next for the brand.

How A German Vape Company Revolutionized Cannabis Consumption Forever: The Inside Story Of Storz &amp; Bickel



Alcohol is generally inelastic as prices rise; demand tends to remain the same. However, this doesn’t mean consumers can’t trade down or switch types of alcohol. Constellation Brands Inc. (NYSE:STZ) is one

Constellation Brands: A Fallen Star or a Hidden Value Play?

Wall-Street-ai7-1

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Government

Macro Economic Events

Regulations

Bonds

Broad U.S. Equity ETFs

Commodities

Forex

Econ #s

Economics

ETFs

$BTC

AFRM

AMZN

AVTR

CBOE

SPDR Dow Jones Industrial Average ETF Trust

EXPE

FTNT

GPRE

ILMN

ITRM

MPWR

PAGP

PINS

POST

PRLB

PowerShares Exchange Traded Fund Trust Dynamic Mid Cap Value Portfolio

ROAD

SSNC

iShares Trust Barclays 20+ Year Treasury Bond Fund

TTWO

UBER

ULCC

PowerShares DB US Dollar Index Bullish Fund

VRSN

XLRE

Select Sector SPDR-Consumer Discretionary

Wall Street slumped into negative territory late in the week as renewed fears over inflation and trade tariffs eroded risk appetite. 

Wall Street Drops On Tariffs Threat, Dollar Rises, Uber Rockets On Ackman&#39;s Tweet: What&#39;s Driving Markets Friday?

Canopy Growth Corporation - Common Shares

Canopy Growth Corp

Capital Group Core Bond ETF

CENTRAL GLASS CO LTD ORD by Central Glass Co., Ltd.

Central Glass Co Ltd

Commerce Group Corp

Capital Group Core Plus Income ETF

Capital Group Conservative Equity ETF

&#8220;The cannabis world is always growing. It's a steady and slow process, but it never stops,&#8221; says Jürgen Bickel, managing director and co-founder of STORZ &amp; BICKEL. For more than two decades, he has been at the forefront of innovation in vaporization, transforming the way consumers and patients experience cannabis.
From launching the Volcano in 2000, before most people even knew vaporization was possible, to the release of the VENTY, hailed as 2024's Vaporizer of the Year at <a href="https://www.benzinga.com/24/12/42371474/benzingas-javier-hasse-recognized-as-cannabis-journalist-of-the-year-at-emjays-awards-2024">the EMJAYS</a>, Bickel's approach has always been methodical, science-driven and focused on the user experience. But even after years of refining vaporization technology, he insists: there's still work to be done.
<h2 class="wp-block-heading">A Legacy Of Innovation: The Birth Of STORZ &amp; BICKEL</h2>
Before vaporization became mainstream, before dry herb vapes lined dispensary shelves, there was the Volcano.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="684" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12140209/Hybrid_1-1024x684.jpg" alt="" class="wp-image-779469" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12140209/Hybrid_1-1024x684.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12140209/Hybrid_1-300x200.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12140209/Hybrid_1-768x513.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12140209/Hybrid_1-1536x1025.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12140209/Hybrid_1.jpg 1618w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
The story begins in the late 1990s with Markus Storz, a graphic designer in Germany who started experimenting with hot air extraction as an alternative to combustion. The concept was simple yet groundbreaking: heat cannabis just enough to release cannabinoids and terpenes, but not enough to burn it—eliminating harmful byproducts associated with smoking.
At the time, vaporization was almost unheard of. The idea that you could consume cannabis without combustion was revolutionary, especially for medical patients looking for a healthier alternative.
See also: <a href="https://www.benzinga.com/markets/cannabis/25/02/43558897/exclusive-doordash-reveals-why-its-betting-on-thc-cbd-delivery">EXCLUSIVE: DoorDash Reveals Why It&#8217;s Betting On THC, CBD Delivery</a>
Bickel, an engineer by trade, saw the potential in Storz's work and joined forces with him in the early 2000s. Together, they refined the design and introduced a forced-air system that would become the hallmark of the Volcano.
&#8220;People didn't even realize you could inhale cannabis without smoking it,&#8221; Bickel recalls. &#8220;It was a novelty. But once they tried it, they understood the benefits immediately.&#8221;
The balloon-based delivery system wasn't just a design choice: it was a game-changer. It separated heat generation from inhalation, ensuring consistent, safe and controlled dosing. For medical marijuana users, this was particularly critical.
&#8220;Once it's in the balloon, there's no heat, no electricity—it's very safe,&#8221; Bickel explains. &#8220;You can fall asleep with it, and it doesn't matter. You can easily inhale at your own pace.&#8221;
<h2 class="wp-block-heading">Engineering The Future Of Vaporization—One Device At A Time</h2>
While the Volcano, which turns 25 years old in 2025, remains an industry staple, STORZ &amp; BICKEL didn't stop there. Over the years, the company expanded its product line, refining vaporization technology for different user preferences.
<ul>
<li>2007: The Volcano Digit introduced precise digital temperature controls.</li>
<li>2014: The Mighty and Crafty brought portable, battery-powered convection heating.</li>
<li>2019: The Volcano Hybrid combined balloon and whip inhalation for more flexibility.</li>
<li>2023: The VENTY—STORZ &amp; BICKEL's fastest, most customizable vaporizer yet—set a new standard in airflow and heat-up speed.</li>
</ul>
The company's approach has always been methodical, balancing scientific research, precision engineering and user feedback.
See also: <a href="https://www.benzinga.com/markets/cannabis/25/01/43002904/he-worked-on-producing-oxygen-on-mars-now-he-builds-cannabis-robots-the-fascinating-story-of-sorting-robotics">He Worked On Producing Oxygen On Mars, Now He Builds Cannabis Robots: The Fascinating Story Of Sorting Robotics</a>
&#8220;We constantly look at development,&#8221; Bickel explains. &#8220;We like to let new products settle a little bit… but of course, we are always working on new things.&#8221;
This relentless drive for innovation has ensured that STORZ &amp; BICKEL devices are trusted by medical patients and connoisseurs alike, setting the benchmark for quality, performance and reliability in vaporization technology.
<h3 class="wp-block-heading">Medical-Grade Precision: The Key To STORZ &amp; BICKEL's Success</h3>
One of the most defining features of STORZ &amp; BICKEL's devices is their medical-grade quality. The company was the first to receive medical certification for a cannabis vaporizer—an achievement that set it apart from competitors.
Bickel emphasizes the importance of safety and reliability, particularly for medical users. &#8220;It was never just about innovation for the sake of it—we wanted to make something that actually improved the way people consumed cannabis.&#8221; 
This focus on precision and consistency has made STORZ &amp; BICKEL the go-to brand for medical cannabis patients, researchers, and connoisseurs alike. By prioritizing quality over trends, the company has maintained its reputation as the gold standard in vaporization.
<h2 class="wp-block-heading">The VENTY: Faster, Stronger And More Efficient</h2>
In October 2023, STORZ &amp; BICKEL introduced the VENTY, a vaporizer designed to push the limits of speed, airflow and efficiency.
See also: <a href="https://www.benzinga.com/markets/cannabis/25/01/42962940/this-is-how-you-make-quality-joints-how-one-machine-produces-900-pre-rolls-an-hour-and-why-theyre-better-than-cones">&#8216;This Is How You Make Quality Joints&#8217; &#8211; How One Machine Produces 900 Pre-Rolls An Hour And Why They&#8217;re Better Than Cones</a>
&#8220;The VENTY heats up in just 20 seconds,&#8221; says Bickel. &#8220;It has a lot of draw possibility—the airflow is very high.&#8221;
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="683" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12140331/Copy-of-_DSC3888-2-1024x683.jpg" alt="" class="wp-image-779470" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12140331/Copy-of-_DSC3888-2-1024x683.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12140331/Copy-of-_DSC3888-2-300x200.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12140331/Copy-of-_DSC3888-2-768x512.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12140331/Copy-of-_DSC3888-2-1536x1025.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12140331/Copy-of-_DSC3888-2.jpg 1619w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">&#xA9;Andi Singer www.andisinger.net</figcaption></figure>
With its adjustable airflow system, users can fine-tune the resistance to match their preferences, making the experience more dynamic and customizable than ever before. The dual lithium-ion battery also ensures extended use, reducing the need for frequent recharging.
&#8220;We are always working on development,&#8221; Bickel repeats. &#8220;With the VENTY, we brought out a really great device.&#8221;
<h2 class="wp-block-heading">The Canopy Growth Acquisition: What Changed?</h2>
In 2018, STORZ &amp; BICKEL was <a href="https://www.benzinga.com/markets/cannabis/18/12/12807167/canopy-growth-to-acquire-cannabis-vaporizer-maker-storz-bickel">acquired</a> by Canopy Growth Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>), one of the largest cannabis companies in the world, in a $145 million deal. The move came at a time when Canopy was rapidly expanding, securing global assets to strengthen its market position.
&#8220;There was a moment in the company's life when we decided to sell,&#8221; Bickel recalls. &#8220;We had a very good offer at the time. There were personal reasons for the decision, but also the opportunity made sense.&#8221;
Despite the acquisition, STORZ &amp; BICKEL has maintained operational independence, with Bickel still leading the company as managing director.
&#8220;Nothing changed in terms of how we develop our products or how we interact with our customers,&#8221; he says. &#8220;We still focus on what we do best: making the highest-quality vaporizers in the world.&#8221;
Being part of a larger corporation has also helped expand STORZ &amp; BICKEL's international reach, providing access to greater resources while allowing the brand to continue innovating at its own pace.
<h2 class="wp-block-heading">What's Next For STORZ &amp; BICKEL?</h2>
With the success of the VENTY and a legacy spanning over two decades, what's next for STORZ &amp; BICKEL?
&#8220;Right now, we're focused on letting the VENTY settle into the market,&#8221; Bickel says. &#8220;But, of course, we're always working on new things.&#8221;
While the company remains tight-lipped about upcoming product developments, STORZ &amp; BICKEL is actively expanding its presence beyond devices. The brand is forging strategic partnerships in the growing consumption lounge sector, starting with The Woods, a cannabis lounge co-founded by Woody Harrelson. These collaborations aim to enhance the consumer experience while positioning the VOLCANO Hybrid and VENTY as must-have devices in high-end, social consumption settings.
The company also made history at Super Bowl 59, becoming the first cannabis brand to host an on-site consumption event at Sports Illustrated's The Party. The VOLCANO Bar, featuring CEO Jürgen Bickel and retired NFL star Pacman Jones, introduced football fans to high-end, smoke-free vaporization—marking a milestone for mainstream cannabis acceptance.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="819" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12140136/VolcanoBar_Pacman-1024x819.jpg" alt="" class="wp-image-779462" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12140136/VolcanoBar_Pacman-1024x819.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12140136/VolcanoBar_Pacman-300x240.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12140136/VolcanoBar_Pacman-768x614.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12140136/VolcanoBar_Pacman.jpg 1350w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
With cannabis culture evolving and public consumption spaces becoming more popular, STORZ &amp; BICKEL is well-positioned to remain at the forefront of innovation—not just in technology, but in how and where people experience cannabis.
&#8220;The cannabis world keeps growing, and we'll continue to evolve with it,&#8221; Bickel says.
Photo courtesy of STORZ &amp; BICKEL

How A German Vape Company Revolutionized Cannabis Consumption Forever: The Inside Story Of Storz & Bickel

News

Markets

General

Canopy Growth Announced The Expansion Of Its Deep Space Propulsion Beverage Lineup With Two New Flavors: Rocket Root Beer And Charged Cream Soda

<a href="https://themarijuanaherald.com/2025/02/dea-official-says-marijuana-rescheduling-is-delayed-but-certainly-not-dead/" title="https://themarijuanaherald.com/2025/02/dea-official-says-marijuana-rescheduling-is-delayed-but-certainly-not-dead/">https://themarijuanaherald.com/2025/02/dea-official-says-marijuana-rescheduling-is-delayed-but-certainly-not-dead/</a>

Biotech

Legal

AKAN

CRON

GRWG

IMCC

LFLY

MAPS

MSOS

SNDL

TLRY

"DEA Official Says Marijuana Rescheduling Is 'Delayed, But Certainly Not Dead'" - The Marijuana Herald

Wall Street slumped into negative territory late in the week as renewed fears over inflation and trade <a href="https://www.benzinga.com/topic/tariffs">tariffs eroded risk appetite. </a>
The first warning sign came from the University of Michigan's consumer sentiment survey, which revealed an "unusually large" spike in inflation expectations. The one-year inflation outlook surged by a full percentage point to 4.3%, marking its highest <a href="https://www.benzinga.com/25/02/43564020/consumer-sentiment-sinks-economist-flags-unusually-large-rise-in-inflation-perception">level since November 2023. </a>
Investor uncertainty grew following President Donald Trump's announcement that &#8216;reciprocal tariffs&#8217; would take effect next week. Trump is expected to sign new executive orders at 2:00 p.m. Friday.
On the macro front, February&#8217;s jobs report revealed a mixed outcome, with employment growth slowing down more than expected, yet unemployment fell more than expected, and wages surged more than expected.
Market reaction was swift. The S&amp;P 500 fell 0.6%, erasing its weekly gains, while the Nasdaq 100 dropped 0.9% by 1:00 p.m. trading in New York. 
The Dow Jones Industrial Average slipped into negative territory for the week, putting its three-week winning streak at risk. Small-cap stocks underperformed, with the Russell 2000 sinking 1.3%. 
Stock-wise, Uber Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NASDAQ">UBER</a>) skyrocketed by 9.5%, extending its 8.6% rally from the previous session, after hedge fund billionaire Bill Ackman revealed a stake of 30.3 million shares in the ride-hailing giant.
In currency and bond markets, the U.S. dollar index – tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) – rallied following the tariff headlines, while Treasury yields climbed higher. The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) dropped 0.8%, reflecting renewed pressure on long-duration bonds. 
Gold took a breather, retreating under pressure from a stronger dollar. Meanwhile, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) erased early session gains, slipping from an intraday high of $100,000 to $97,500.
<h3 class="wp-block-heading">Friday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>• S&amp;P 500</td>
<td>6,047.11</td>
<td>-0.6%</td>
</tr>
<tr>
<td>• Dow Jones</td>
<td>44,452.38</td>
<td>-0.7%</td>
</tr>
<tr>
<td>• Nasdaq 100</td>
<td>21,576.82</td>
<td>-0.9%</td>
</tr>
<tr>
<td>• Russell 2000</td>
<td>2,279.74</td>
<td>-1.2%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 1:00 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;fell 0.6% to $602.79.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) fell 0.7% to $444.45.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;dropped 0.8% up to $528.47.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) flattened at $229.55.</li>
<li>The&nbsp;Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) outperformed, up 0.7%; the&nbsp;Consumer Discretionary Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) lagged, down 1.2%.</li>
</ul>
<h3 class="wp-block-heading">Friday&#8217;s Stock Movers</h3>
Stocks reacting to earnings reports included:
<ul>
<li>Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>): down 3.78%</li>
<li>Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>): down 8.29%</li>
<li>Fortinet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>): up 2.86%</li>
<li>Expedia Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>): up 15.22%</li>
<li>Take-Two Interactive Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>): up 14.92%</li>
<li>Monolithic Power Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>): up 7.06%</li>
<li>Pinterest Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>): up 17.09%</li>
<li>SS&amp;C Technologies Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSNC#NASDAQ">SSNC</a>): up 5.44%</li>
<li>Principal Financial Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFG#NASDAQ">PFG</a>): up 1.55%</li>
<li>Mettler-Toledo International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTD#NYSE">MTD</a>): up 2.12%</li>
<li>AptarGroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATR#NYSE">ATR</a>): down 7.08%</li>
<li>Post Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POST#NYSE">POST</a>): up 5.96%</li>
<li>Mohawk Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHK#NYSE">MHK</a>): down 1.53%</li>
<li>Boyd Gaming Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYD#NYSE">BYD</a>): down 0.76%</li>
<li>Encompass Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHC#NYSE">EHC</a>): up 1.53%</li>
<li>VeriSign Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSN#NASDAQ">VRSN</a>): down 0.32%</li>
<li>Cloudflare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>): up 18.39%</li>
<li>Skechers USA Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>): down 12.68%</li>
<li>Affirm Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>): up 23.22%</li>
<li>e.l.f. Beauty Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>): down 21.12%</li>
<li>Fortive Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTV#NYSE">FTV</a>): down 1.64%</li>
<li>Kimco Realty Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KIM#NYSE">KIM</a>): up 0.20%</li>
<li>Avantor Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>): down 9.52%</li>
<li>Plains All American Pipeline LP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAA#NASDAQ">PAA</a>): down 2.65%</li>
<li>Cboe Global Markets Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBOE#NASDAQ">CBOE</a>): up 1.03%</li>
<li>Construction Partners Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROAD#NASDAQ">ROAD</a>): up 6.75%</li>
<li>Plains GP Holdings LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAGP#NYSE">PAGP</a>): down 1.56%</li>
<li>Flowers Foods Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLO#NYSE">FLO</a>): up 0.31%</li>
<li>Newell Brands Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>): down 28.38%</li>
<li>Perella Weinberg Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PWP#NASDAQ">PWP</a>): down 6.50%</li>
<li>Frontier Group Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULCC#NASDAQ">ULCC</a>): up 16.75%</li>
<li>Proto Labs Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NYSE">PRLB</a>): down 1.89%</li>
<li>Green Plains Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPRE#NASDAQ">GPRE</a>): down 19.06%</li>
<li>Graham Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GHM#NYSE">GHM</a>): down 17.34%</li>
<li>GrafTech International Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAF#NYSE">EAF</a>): down 4.70%</li>
<li>Canopy Growth Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>): down 25.18%</li>
<li>Iterum Therapeutics plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRM#NASDAQ">ITRM</a>): down 5.03%</li>
</ul>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43567475/amazon-vs-walmart-did-amazons-q4-revenue-beat-the-worlds-largest-retailer">Amazon Vs. Walmart: Did Amazon&#8217;s Q4 Revenue Beat &#8216;The World&#8217;s Largest Retailer&#8217;?</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Wall Street Drops On Tariffs Threat, Dollar Rises, Uber Rockets On Ackman's Tweet: What's Driving Markets Friday?

From political maneuvering in Washington to major corporate developments across the global cannabis landscape, this week has been packed with pivotal moments for the industry. In the U.S., Florida Governor Ron DeSantis is doubling down on his opposition to recreational cannabis, predicting that a renewed 2026 ballot initiative will face &#8220;big-time trouble.&#8221;
On the business side, Village Farms International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) officially launched sales in the Netherlands, marking a significant milestone for Europe&#8217;s evolving cannabis market. In Canada, Aurora Cannabis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) reported a <a href="https://www.benzinga.com/markets/cannabis/25/02/43498531/why-aurora-cannabis-stock-is-skyrocketing-today-what-about-canopy-tilray-and-cronos">record-breaking quarter</a> with soaring international sales, while Canopy Growth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) managed to <a href="https://www.benzinga.com/general/health-care/25/02/43562398/why-is-canada-based-cannabis-firm-canopy-growth-stock-trading-lower-on-friday">exceed revenue expectations</a> despite ongoing struggles in the consumer sector.
In New York, a <a href="https://www.benzinga.com/markets/cannabis/25/02/43541317/inside-new-yorks-bold-plan-to-decriminalize-drug-possession">new bill aims to decriminalize all drug possession</a>, a move that could reshape the state&#8217;s approach to substance use. Meanwhile, Chile is facing political controversy as lawmaker and cannabis advocate <a href="https://www.benzinga.com/25/02/43561786/why-this-lawmaker-refuses-to-take-a-mandatory-drug-test-drama-in-the-chilean-congress">Ana María Gazmuri</a> challenges the country's mandatory drug testing policy for public officials.
On the lifestyle front, Tilray Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) continues expanding into the craft beer market with a <a href="https://www.benzinga.com/markets/cannabis/25/02/43537012/cannabis-giant-tilray-doubles-down-on-its-beer-business-with-new-jetblue-partnership">high-profile partnership</a> placing Montauk Brewing beers on JetBlue (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) flights. And in an industry-first, New York cannabis retailer The Travel Agency has secured ad space in Playbill, bringing legal cannabis into Broadway's mainstream culture.
Now, let&#8217;s break down the biggest stories of the week.
<h2 class="wp-block-heading">In Today&#8217;s Issue Of &#8216;The Week In Cannabis&#8217;</h2>
Politics &amp; Policy
<ul>
<li>DeSantis: Florida Legalization Faces ‘Big-Time Trouble' in 2026</li>
<li>New York Bill Proposes Full Drug Decriminalization</li>
</ul>
Market &amp; Business Developments
<ul>
<li>Village Farms Begins Legal Cannabis Sales in the Netherlands</li>
<li>Aurora Cannabis Reports Record Medical Sales Growth</li>
<li>Canopy Growth Beats Revenue Expectations Despite Challenges</li>
<li>iAnthus Sells Arizona Assets for $36.5M to Sonoran Roots</li>
<li>Tilray Expands Craft Beer Reach with JetBlue Partnership</li>
</ul>
Culture &amp; Regulation
<ul>
<li>Chilean Lawmaker Fights Mandatory Drug Testing for Officials</li>
<li>Panama Approves Hemp Law After Years of Delays</li>
<li>New York's Cannabis Scene Breaks into Broadway</li>
</ul>
Industry Trends &amp; Market Analysis
<ul>
<li>US Cannabis Growth Slows, Business Failures Rise</li>
<li>Elon Musk Pushes Drug Testing for Federal Employees</li>
</ul>
<h2 class="wp-block-heading">Politics And Policy: Reform In The Spotlight</h2>
<h4 class="wp-block-heading">DeSantis: Florida Legalization Faces ‘Big-Time Trouble' in 2026</h4>
Florida Governor Ron DeSantis has already set his sights on stopping a new recreational cannabis ballot initiative for 2026, after the 2024 measure failed to reach the 60% approval needed. He warned that the initiative will struggle to make it onto the ballot, citing expected legal challenges from the Florida Supreme Court.
Comparing cannabis policy to &#8220;pregnant pig care in the U.S. Constitution,&#8221; DeSantis argued that legalization should be left to lawmakers, not voter referendums. Meanwhile, Florida's medical cannabis industry remains one of the nation's most profitable, making the state a key battleground for reform.
<h4 class="wp-block-heading">New York Bill Proposes Full Drug Decriminalization</h4>
New York lawmakers introduced Senate Bill S3600, aiming to eliminate criminal and civil penalties for personal drug possession, shifting policy toward public health. Sponsored by State Senator Gustavo Rivera, the bill would expunge past convictions, prevent penalties for parolees, and replace arrests with fines or treatment referrals.
The proposal follows global models in Portugal and Oregon that have reduced overdoses and incarceration. Critics warn that New York must expand treatment access before decriminalization, but supporters argue it's a necessary step to end ineffective drug criminalization.
<h2 class="wp-block-heading">Market And Business Developments: Expansion, Earnings And Deals</h2>
<h4 class="wp-block-heading">Village Farms Begins Legal Cannabis Sales In The Netherlands</h4>
Village Farms International has officially launched cannabis sales in the Netherlands through its wholly owned subsidiary, Leli Holland. The company completed its first harvest in December and will begin supplying Dutch coffeeshops on February 7.
Leli Holland is one of 10 licensed producers in the country's regulated recreational cannabis program. Village Farms CEO Michael DeGiglio called the Dutch market &#8220;one of the most attractive cannabis investment opportunities globally,&#8221; citing strong demand, a favorable pricing environment, and a zero-tax policy on regulated products. Full-scale operations are expected by Q2 2025.
<h4 class="wp-block-heading">Aurora Cannabis Reports Record Medical Sales Growth</h4>
Aurora Cannabis posted a 37% revenue increase in Q3 2025, reaching CA$88.2 million, with its global medical cannabis business growing 51%. CEO Miguel Martin highlighted all-time highs in medical sales, net income and free cash flow.
International medical cannabis sales surged in markets like Australia, Germany, Poland and the UK, helping offset a 15% decline in consumer cannabis revenue. The company also saw a 22% increase in plant propagation revenue. Aurora expects further growth next quarter, driven by international expansion and seasonal demand for plant propagation.
<h4 class="wp-block-heading">Canopy Growth Beats Revenue Expectations Despite Challenges</h4>
Canopy Growth reported Q3 sales of CA$74.76 million, surpassing analyst expectations but reflecting an overall decline from the previous year. Growth in Canada's medical cannabis and international markets offset weaker performance in the consumer sector.
CEO Luc Mongeau pointed to strong medical cannabis sales, Storz &amp; Bickel vaporizer revenue and the launch of Claybourne-infused pre-rolls in Canada as key drivers. Adjusted EBITDA improved significantly year-over-year, but challenges remain as the company navigates shifting consumer demand.
<h4 class="wp-block-heading">iAnthus Sells Arizona Assets For $36.5M To Sonoran Roots</h4>
iAnthus Capital Holdings (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) is selling three dispensaries and two processing facilities in Arizona to Sonoran Roots for $36.5 million. The deal includes $20 million in cash and a $16.5 million secured promissory note.
The move aligns with iAnthus' strategy to focus on key markets like Florida, Maryland, New Jersey and New York. CEO Richard Proud said the sale will help the company &#8220;double down on markets where we can deliver the most value to our customers.&#8221; iAnthus will maintain one dispensary in Mesa and continue selling its MPX brand in Arizona.
<h4 class="wp-block-heading">Tilray Expands Craft Beer Reach with JetBlue Partnership</h4>
Tilray Brands continues its push into the alcohol market with a new partnership placing Montauk Brewing's Surf Beer Golden Ale on all JetBlue flights. The deal marks the first time JetBlue will serve Montauk's flagship beer, giving the cannabis company greater exposure in mainstream beverage distribution.
Tilray has aggressively expanded its beer portfolio through acquisitions of brands like SweetWater, Blue Point and Shock Top. While cannabis remains its core business, CEO Irwin Simon has positioned Tilray's beverage division as a strategic bridge for future cannabis-infused drinks once regulations allow.
<h2 class="wp-block-heading">Culture And Regulation: Cannabis In Society And Policy Shifts</h2>
<h4 class="wp-block-heading">Chilean Lawmaker Fights Mandatory Drug Testing for Officials</h4>
A political storm erupted in Chile's Congress after lawmaker and longtime cannabis advocate Ana María Gazmuri refused to comply with mandatory biannual drug testing for public officials. As a result, she was penalized with a 15% salary reduction, but she remains defiant, calling the policy &#8220;poorly designed, lacking transparency, and infringing on fundamental rights.&#8221;
Gazmuri, a medical cannabis user with a legal prescription, also disclosed her guided use of psilocybin mushrooms but emphasized that her refusal to take the test was about principle, not personal drug use. She argued that if the real goal is uncovering ties between politicians and drug trafficking, financial investigations should take priority.
Right-wing lawmakers have responded by proposing a constitutional amendment that would remove any public official who consumes illegal substances. Gazmuri, however, remains firm in her stance, vowing to continue pushing for broader drug policy reform.
<h4 class="wp-block-heading">Panama Approves Hemp Law After Years Of Delays</h4>
Panama's long-awaited hemp regulation finally passed after years of bureaucratic delays, clearing the way for industrial hemp production, commercialization and export. The legislation had been stalled under the previous administration but gained momentum with new lawmakers and business sector support.
Advocates argue the new hemp industry could create jobs, attract investment and even help alleviate Panama's struggling social security system. However, the fate of the law now rests with President José Raúl Mulino, who has yet to sign it. If approved, Panama could position itself as a leader in the regional hemp market.
<h4 class="wp-block-heading">New York's Cannabis Scene Breaks Into Broadway</h4>
New York cannabis retailer The Travel Agency has made history as the first marijuana business to advertise in Playbill, the iconic magazine of Broadway theater goers. The campaign, which promotes cannabis as a way to &#8220;Experience a Matinee for Your Mind,&#8221; coincides with the company opening a third retail store near Radio City Music Hall.
The Travel Agency has also partnered with Broadway productions like An Axemas Story and launched an online guide featuring cannabis products tailored for theater lovers. Industry insiders see this as a major step in normalizing cannabis within mainstream cultural spaces.
<h2 class="wp-block-heading">Industry Trends And Market Analysis: Growth, Struggles And The Road Ahead</h2>
<h4 class="wp-block-heading">US Cannabis Growth Slows, Business Failures Rise</h4>
Despite posting its 11th consecutive year of revenue growth, the US legal cannabis industry saw its expansion slow in 2024, with sales increasing just 6% to around $30.5 billion, according to Whitney Economics.
The number of struggling businesses is rising, with nearly 1,000 fewer active cannabis licenses by year's end. A staggering 72.7% of operators reported being unprofitable, with many blaming federal inaction on banking, tax reform, and interstate commerce.
Michigan was a rare bright spot, hitting $3.3 billion in sales, partially fueled by out-of-state buyers. New York also exceeded expectations after regulatory changes, while Florida underperformed due to a slowdown in medical patient registrations. Meanwhile, mature markets like Colorado, Oregon, and Washington saw demand flatten or decline.
Whitney Economics warns that without major policy changes, business failures will continue accelerating in 2025.
<h4 class="wp-block-heading">Elon Musk Pushes Drug Testing For Federal Employees</h4>
Elon Musk has thrown his support behind a proposal for mandatory, immediate drug testing across the federal workforce, a move that aligns with his broader push to shrink government operations.
The idea, first floated by former National Security Council official Joshua Steinman, was met with Musk's simple endorsement: &#8220;Great idea.&#8220; While federal employees in certain positions already undergo drug screenings, Musk's proposal could drastically expand testing.
Ironically, Musk himself was subjected to random drug tests for a year after smoking cannabis on Joe Rogan's podcast in 2018. He has since spoken openly about using ketamine for depression and has supported psychedelics research.
His latest stance comes as Senator Elizabeth Warren has urged Musk to cut &#8220;wasteful&#8220; spending on cannabis enforcement, a move that could save hundreds of millions annually. Whether Musk will act on that remains to be seen.

Earnings

Latin America

Politics

ITHUF

JBLU

This Week In Cannabis: DeSantis' Anti-Weed Push, NY's Drug Decriminalization, Aurora's Record Earnings, Tilray And More Global News

On Friday, Canopy Growth Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) reported third-quarter 2025 sales of CA$74.76 million, down from CA$78.51 million a year ago, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of CA$69.11 million</a>.
Excluding net revenue from businesses divested during the prior fiscal year, net revenue increased 8%, driven primarily by growth in Canada&#8217;s medical, international <a href="https://www.benzinga.com/pressreleases/25/02/n43556485/canopy-growth-reports-third-quarter-fiscal-year-2025-financial-results" target="_blank" rel="noreferrer noopener">markets and Storz &amp; Bickel</a>.
Cannabis net revenue was CA$41 million, up 1%. Medical cannabis net revenue increased 16% compared, driven primarily by an increase in the average size of medical orders placed by customers.
Also Read: <a href="https://www.benzinga.com/markets/cannabis/25/02/43498531/why-aurora-cannabis-stock-is-skyrocketing-today-what-about-canopy-tilray-and-cronos" target="_blank" rel="noreferrer noopener">Why Aurora Cannabis Stock Is Skyrocketing Wednesday: What About Canopy, Tilray, Cronos?</a>
Adult-use cannabis net revenue declined 10%.
Storz &amp; Bickel delivered net revenue of CA$22 million, representing a 19% increase, driven by traditionally strong holiday purchases, robust direct-to-consumer online sales and continued growth in Germany.
&#8220;Canopy Growth&#8217;s third quarter highlights that our business has the right ingredients for success, as demonstrated by the continued momentum in our medical cannabis businesses, Storz &amp; Bickel, and the successful introduction of Claybourne infused pre-rolls in Canada,&#8221; said CEO Luc Mongeau.
&#8220;The third quarter marked our best Adjusted EBITDA to date, led by strong year-over-year top-line growth in our medical cannabis business and Storz &amp; Bickel, and continued cost discipline,&#8221; Mongeau added.
Gross margin decreased by 400 basis points to 32%, primarily due to the incremental costs related to the Claybourne-infused pre-roll launch in Canada and an increase in indirect costs of Storz &amp; Bickel vaporizer devices partially offset by stronger sales of higher-margin medical cannabis products.
Operating loss was CA$24 million, representing an improvement of 61%. Adjusted EBITDA loss of $3 million, representing a 61% improvement year-over-year, driven primarily by the realized benefit of the company&#8217;s cost savings program.
Price Action: CGC stock is down 23.4% at $2.13 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43560312/life-science-tools-firm-avantor-reports-mixed-q4-earnings-forecasts-organic-sales-growth-in-2025" target="_blank" rel="noreferrer noopener">Life Science Tools Firm Avantor Reports Mixed Q4 Earnings, Forecasts Organic Sales Growth In 2025</a></li>
</ul>

Health Care

Retail Sales

Movers

Trading Ideas

Why Is Canada-Based Cannabis Firm Canopy Growth Stock Trading Lower On Friday?

Canopy Gwth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) reported its Q3 earnings results on Friday, February 7, 2025 at 07:00 AM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Canopy Gwth missed estimated earnings by -65.0%, reporting an EPS of $-0.79 versus an estimate of $-0.48.
Revenue was down $4.51 million from the same period last year.
<h3>Previous Earnings Records</h3>
During the previous quarter, the company missed on EPS by $0.84, leading to a 7.000000000000001% drop share price change the next day.
Here's a look at Canopy Gwth's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.27</td>
<td>-0.35</td>
<td>-0.33</td>
<td>-0.37</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.11</td>
<td>-1.19</td>
<td>-0.79</td>
<td>-2.04</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>47.14M</td>
<td>53.84M</td>
<td>53.06M</td>
<td>55.44M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>46.17M</td>
<td>48.40M</td>
<td>54.00M</td>
<td>66.17M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Canopy Gwth <a href="https://www.benzinga.com/quote/CGC/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Canopy Gwth Q3 Earnings Assessment

WIIM

Canopy Growth shares are trading lower following Q3 earnings.

Canopy Growth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) reported quarterly losses of $(1.11) per share which missed the analyst consensus estimate of $(0.55) by 101.82 percent. This is a 57.63 percent increase over losses of $(2.62) per share from the same period last year. The company reported quarterly sales of $74.76 million which beat the analyst consensus estimate of $69.11 million by 8.18 percent. This is a 4.77 percent decrease over sales of $78.50 million the same period last year.

Canopy Growth Q3 2025 GAAP EPS C$(1.11) May Not Be Comparable To C$(0.55) Estimate, Sales C$74.76M Beat C$69.11M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Cboe Global Markets (BATS:<a class="ticker" href="https://www.benzinga.com/stock/CBOE#BATS">CBOE</a>) is expected to report quarterly earnings at $2.12 per share on revenue of $526.93 million. 
• Kimco Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KIM#NYSE">KIM</a>) is expected to report quarterly earnings at $0.42 per share on revenue of $510.83 million. 
• Bank Bradesco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBD#NYSE">BBD</a>) is likely to report quarterly earnings at $0.09 per share on revenue of $6.10 billion. 
• Frontier Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULCC#NASDAQ">ULCC</a>) is expected to report quarterly earnings at $0.13 per share on revenue of $986.50 million. 
• Plains GP Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAGP#NASDAQ">PAGP</a>) is projected to report quarterly earnings at $0.46 per share on revenue of $14.68 billion. 
• Plains All American (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAA#NASDAQ">PAA</a>) is estimated to report quarterly earnings at $0.43 per share on revenue of $13.95 billion. 
• Newell Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>) is expected to report quarterly earnings at $0.14 per share on revenue of $1.96 billion. 
• Iterum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRM#NASDAQ">ITRM</a>) is likely to report earnings for its fourth quarter. 
• Bank Bradesco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBDO#NYSE">BBDO</a>) is expected to report earnings for its fourth quarter. 
• Graham (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GHM#NYSE">GHM</a>) is estimated to report quarterly earnings at $0.08 per share on revenue of $49.50 million. 
• Listed Funds Trust Roundhill Cannabis ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/WEED#BATS">WEED</a>) is expected to report quarterly loss at $0.23 per share on revenue of $69.44 million. 
• Canopy Gwth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) is estimated to report quarterly loss at $0.31 per share on revenue of $69.55 million. 
• Perella Weinberg (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PWP#NASDAQ">PWP</a>) is likely to report quarterly earnings at $0.23 per share on revenue of $222.65 million. 
• Green Plains (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPRE#NASDAQ">GPRE</a>) is estimated to report quarterly loss at $0.21 per share on revenue of $646.03 million. 
• Flowers Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLO#NYSE">FLO</a>) is likely to report quarterly earnings at $0.21 per share on revenue of $1.13 billion. 
• Byrna Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYRN#NASDAQ">BYRN</a>) is projected to report quarterly earnings at $0.04 per share on revenue of $24.33 million. 
• Proto Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NYSE">PRLB</a>) is likely to report quarterly earnings at $0.32 per share on revenue of $120.12 million. 
• Construction Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROAD#NASDAQ">ROAD</a>) is expected to report quarterly earnings at $0.20 per share on revenue of $518.50 million. 
• Banco Santander Chile (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSAC#NYSE">BSAC</a>) is expected to report quarterly earnings at $0.54 per share on revenue of $744.19 million. 
• Avantor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>) is likely to report quarterly earnings at $0.26 per share on revenue of $1.72 billion. 
• Gorman-Rupp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRC#NYSE">GRC</a>) is projected to report quarterly earnings at $0.45 per share on revenue of $162.84 million. 
• GrafTech International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAF#NYSE">EAF</a>) is estimated to report quarterly loss at $0.12 per share on revenue of $131.77 million. 
• Fortive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTV#NYSE">FTV</a>) is projected to report quarterly earnings at $1.12 per share on revenue of $1.63 billion. 
<h3>Companies Reporting After The Bell</h3>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BBDO

BSAC

BYRN

WEED

Earnings Scheduled For February 7, 2025

Options

Canopy Gwth Option Alert: Jun 20 $4 Calls Sweep (12) Near The Ask: 1693 @ $0.43 vs 3974 OI; Earnings 2/7 Before Open Ref=$2.73

Aurora Cannabis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) stock surged more than 45% on Wednesday morning following the release of its <a href="https://www.benzinga.com/news/earnings/25/02/43496003/aurora-cannabis-stock-jumps-on-record-breaking-q3-earnings">third-quarter fiscal 2025 earnings</a>, which revealed a substantial increase in revenue and profitability. The company reported total net revenue of CA$88.2 million ($61.74 million), up 37% year-over-year, driven largely by a 51% jump in its global medical cannabis business.
&#8220;This quarter was record-breaking for Aurora, driven by all-time highs in global medical net revenue, net income, adjusted EBITDA, and free cash flow,&#8221; said Miguel Martin, Aurora's executive chairman and CEO. The company also posted a net income of CA$31.2 million, a 282% year-over-year increase, and an adjusted EBITDA of CA$23.1 million, up 316%.
<h2 class="wp-block-heading">Cannabis Stocks Rally In Sympathy?</h2>
The strong earnings report triggered a broader rally in the cannabis sector, with several companies experiencing notable gains:
<ul>
<li>Canopy Growth Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) jumped over 23%.</li>
<li>Tilray Brands Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) climbed more than 10%.</li>
<li>Cronos Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRON#NASDAQ">CRON</a>) rose approximately 8%.</li>
</ul>
Investors appear to be reacting positively to Aurora's performance, particularly its growing international medical cannabis revenues and improved profitability.
<h2 class="wp-block-heading">Do Trade Tensions Play A Role?</h2>
Beyond earnings, another factor likely contributing to the sector-wide rally is the 30-day delay in U.S.-Canada tariffs, a move that has eased investor concerns. The Trump administration postponed the imposition of 25% tariffs on Canadian imports, providing a window for further trade negotiations. While cannabis wasn't explicitly mentioned in the tariff discussions, the broader economic impact on trade between the countries may be influencing sentiment toward Canadian cannabis companies.
As Aurora continues to expand its medical cannabis footprint globally, investors are closely watching whether the company can sustain its momentum in upcoming quarters.
Illustration made with Canva.

Why Aurora Cannabis Stock Is Skyrocketing Wednesday: What About Canopy, Tilray, Cronos?

BNTX

MRNA

NVAX

Republican Senator Bill Cassidy Votes To Advance Nomination Of Robert F. Kennedy As U.S. HHS Secretary; U.S. Senate Finance Committee Votes 14-13 To Advance Kennedy Nomination Favorably

As Prime Minister Justin Trudeau prepares to step down, Canada&#8217;s <a href="https://www.benzinga.com/cannabis">cannabis industry</a> faces a turning point that could redefine its future. Trudeau's government not only legalized recreational cannabis in 2018, but also positioned Canada as a global leader in marijuana reform, being the first G7 nation to federally legalize cannabis for both medical and adult use. However, the possibility of a new government under Conservative leader Pierre Poilievre introduces concerns about policy stagnation and regulatory rollbacks, raising questions about what's next for this multi-billion-dollar industry.
<h3 class="wp-block-heading">A Legacy Of Legalization</h3>
Trudeau's role in legalizing cannabis has been transformational. As Deepak Anand, principal of British Columbia-based ASDA Consultancy Services, wrote in an opinion piece for <a href="https://mjbizdaily.com/trudeau-departure-is-a-turning-point-for-canadas-cannabis-industry/?utm_campaign=MJBizDaily&amp;utm_medium=email&amp;_hsenc=p2ANqtz--TumbF3n9k5BpRIZG7sq1elN6AqpLc6Tz6h5Y-rxsHhezsVCb2eunNFxbze0rWVlmKKZndySfirNQ3TZaaf4TlIPcY99TZmvdDmeH8k_dvYP9dYOI&amp;_hsmi=343983401&amp;utm_content=343983277&amp;utm_source=hs_email">MJBizDaily</a>, legalization &#8220;not only transformed the nation's social and economic landscape but also established it as a global pioneer in marijuana reform.&#8221; Indeed, a <a href="https://leger360.com/wp-content/uploads/2024/02/PostMedia_CPC-Leadership_Trudeau_July2022.pdf">survey</a> by Leger found that 62% of Canadians support legalization, with many identifying it as one of Trudeau's most significant accomplishments.
Over the past six years, Canada's cannabis industry has generated thousands of jobs, created substantial tax revenue and solidified the country's reputation as a cannabis trailblazer. Yet, as Anand warns, &#8220;storm clouds are gathering on the horizon.&#8221;
<h3 class="wp-block-heading">Risks Under Conservative Leadership</h3>
Anand's analysis highlights the potential risks a Conservative government could bring. Specifically, he points to possible cuts to Health Canada's Controlled Substances and Cannabis Branch, which oversees industry regulations and employs over 200 staff members. &#8220;A Conservative government focused on reducing federal spending could target this department for cuts, potentially creating bottlenecks in licensing processes, amendments, and export license approvals,&#8221; he noted.
Delays in addressing key regulatory reforms, such as marketing restrictions and THC limits on edibles, could make it harder for licensed producers to compete with the illicit market and international competitors. Additionally, Anand noted the stalled progress on expanding CBD sales channels into pharmacies and health food stores, a missed opportunity in tapping into the growing global CBD market.
<h3 class="wp-block-heading">Implications for Publicly Traded Cannabis Companies</h3>
For major players in the cannabis industry like Canopy Growth Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>), Tilray Brands Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) and Aurora Cannabis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>), the uncertainty surrounding Canada's regulatory future could have significant financial implications. Regulatory bottlenecks might hinder these companies' ability to innovate or expand into new markets, while unresolved challenges with THC caps and marketing limitations could affect product appeal and profitability.
Tilray, for instance, has diversified operations into beverages and international markets to offset domestic challenges, but any policy rollback in Canada could limit further opportunities. Similarly, Canopy Growth's strategy to streamline operations and focus on premium products might face headwinds if reform stagnates. Aurora Cannabis, already grappling with financial restructuring, might find it even harder to gain ground without regulatory clarity.
<h3 class="wp-block-heading">The Path Forward</h3>
Anand calls for collective industry action to safeguard Canada's cannabis legacy. He urges stakeholders to proactively engage with policymakers, educate the public and push for reforms to enhance competitiveness and sustainability. &#8220;Cannabis legalization should be viewed as an ongoing process that requires continuous improvement, not as an event having come and gone,&#8221; Anand said.
The stakes are high. Failure to address the industry's needs could jeopardize economic gains, compromise patient access and diminish Canada's standing as a global cannabis leader. For the government, there's a clear imperative: advance reforms before the next election or risk being blamed for creating an unsustainable industry.
As Canada's cannabis industry braces for change, its future will largely depend on the ability of industry leaders and policymakers to work together. Whether under Liberal or Conservative leadership, the need for continuous regulatory improvement remains essential to maintaining Canada's competitive edge in the global cannabis market.
Photo of Justin Trudeau via <a href="https://commons.wikimedia.org/wiki/File:REUNI%C3%93N_CON_JUSTIN_TRUDEAU,_PRIMER_MINISTRO_DE_CANAD%C3%81,_05_DE_MARZO_DE_2024-3.jpg">Wikimedia Commons</a>, edited on Canva.

Can Canada Maintain Its Cannabis Edge After Trudeau's Departure?

This week in cannabis was relatively subdued, with the most significant news stemming from Washington, D.C. The Trump administration appointed a controversial new acting DEA administrator, Derek S. Maltz, raising concerns over the future of cannabis rescheduling efforts. Meanwhile, updates from global markets in Germany, Uruguay and the Netherlands highlighted ongoing industry challenges and progress.
Here's a recap of this week's notable developments.
<h3 class="wp-block-heading">Politics</h3>
<h4 class="wp-block-heading">New DEA Leadership Sparks Cannabis Industry Concerns</h4>
The Trump administration <a href="https://www.benzinga.com/news/global/25/01/43169554/trump-appoints-dea-chief-who-will-bring-ruthless-narco-terrorists-to-justice-not-keen-on-legalizing-cannabis">appointed</a> Derek S. Maltz as the acting administrator of the U.S. Drug Enforcement Administration (DEA). A 28-year veteran of the agency, Maltz is known for his hardline stance on cannabis and drug policy. Maltz has criticized cannabis legalization, citing its alleged links to public safety concerns, and accused the Department of Justice of politicizing the cannabis rescheduling process.
"President Trump is off to a fast start as the 47th POTUS with border security and the horrible implications of cartels and drug trafficking in America as an area of major importance, so we are not surprised by the recent appointment of Derek Maltz as the Acting Administrator of the US DEA,&#8221; said Morgan Paxhia, co-founder and Managing Partner of <a href="https://mattio-dot-yamm-track.appspot.com/2pFzd1Qgmrif5VxFI2L_TFQmXMMHIhfA-E3vgz1Zem7pnchqPlAFxJWLFa7a_EcC7Kgp3W3RkyDRkUal94Mbleln_0lctmQ4C_TyNorrTe8gVXAycGFqk6OoFkP3yPy0_lG3I18yoHMnpIsHOSNSKxh8Vm_Nxe6qe0qi3fXcOUXZNoPVfc1jR" target="_blank" rel="noreferrer noopener">Poseidon</a>, a burgeoning cannabis investment fund. &#8220;President Trump has been getting smart on legal cannabis, sees the economic benefits and is pro MAGA and DOGE. We think it is better to focus less on any appointee's dated/biased views on cannabis and more so on POTUS as the primary input for potential legislative reform and as it pertains to the scheduling of cannabis."
This leadership change occurs amid significant delays in the DEA&#8217;s hearings on rescheduling cannabis from a Schedule I to a Schedule III substance under the Controlled Substances Act. Critics fear the Trump administration may abandon the process entirely, which could set back cannabis reform efforts.
Read more <a href="https://www.benzinga.com/news/global/25/01/43169554/trump-appoints-dea-chief-who-will-bring-ruthless-narco-terrorists-to-justice-not-keen-on-legalizing-cannabis">here</a>.
<h3 class="wp-block-heading">Markets</h3>
<h4 class="wp-block-heading">Ispire Technology Announces $10 Million Stock Buyback</h4>
In response to market volatility, Ispire Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPR#NASDAQ">ISPR</a>) unveiled a $10 million stock buyback program to boost shareholder confidence. The company reaffirmed its commitment to long-term growth despite challenges in the broader cannabis market.
<h4 class="wp-block-heading">Earnings Reports On The Horizon</h4>
Cannabis giants are gearing up to report financial results, offering insights into the industry's trajectory:
<ul>
<li>Aurora Cannabis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) will release Q3 2025 earnings on February 5, followed by a call at 8:00 a.m. ET.</li>
<li>Canopy Growth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) will publish its Q3 2025 results on February 7, with a webcast at 10:00 a.m. ET.</li>
<li>Green Thumb Industries (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTCQX">GTBIF</a>) will report Q4 and FY2024 results on February 26, accompanied by a call at 5:00 p.m. ET.</li>
</ul>
<h3 class="wp-block-heading">Global Updates</h3>
<h4 class="wp-block-heading">Uruguay's Cannabis Market Sees Record Sales</h4>
<a href="https://elplanteo.com/uruguay-2024-compradores-cannabis-legal/">Uruguay</a>'s regulated cannabis market hit new highs in 2024, with over 102,000 registered buyers and annual revenues of $30 million. The introduction of high-THC variants like <a href="https://elplanteo.com/uruguay-cannabis-thc-epsilon/">Épsilon</a> (20% THC) drove demand, with pharmacies selling 359 kilograms in just two months after its launch. The country continues to reduce illegal market activity, now capturing 50% of what was once unregulated sales.
<h4 class="wp-block-heading">Aurora Cannabis Launches First German-Cultivated Product</h4>
Aurora debuted its first German-cultivated medical cannabis product, IndiMed, marking a milestone for Europe's largest medical cannabis market. The launch highlights Aurora's commitment to premium, pharmaceutical-grade products, positioning the company as a leader in navigating complex European regulations.
<h4 class="wp-block-heading">Contaminated Cannabis Found In Dutch Coffee Shops</h4>
A study by the Trimbos Institute revealed alarming levels of contaminants in cannabis sold in Dutch coffee shops. Out of 50 samples tested, one-fifth showed microbiological contamination, and one-third contained pesticide residues. Notably, some samples had lead levels nearly six times the permissible limit under forthcoming regulations for a government-licensed trial.
The trial, set to launch in April, aims to improve quality control and curb illegal activity by introducing state-regulated cannabis supply chains. These findings underscore the urgent need for tighter oversight and regulations to ensure consumer safety in one of the world's oldest legal cannabis markets.
<h3 class="wp-block-heading">Celebrity Advocacy: Tyson and Angelos Applaud Trump's Reforms</h3>
Mike Tyson and Weldon Angelos <a href="https://www.benzinga.com/news/legal/25/01/43149460/trumps-cannabis-reform-mike-tyson-weldon-angelos-say-president-can-get-it-done">commended</a> President Trump for his commitment to cannabis reforms, including rescheduling efforts, banking access and clemency for non-violent cannabis offenders. Tyson called the cannabis industry a "multi-billion-dollar market" that fosters economic growth, while Angelos criticized the Biden administration's lackluster efforts on clemency for marijuana-related convictions.
<h3 class="wp-block-heading">Interesting Reads</h3>
To close up the week, below are some other interesting stories to check out:
<ul>
<li><a href="https://www.forbes.com/sites/javierhasse/2025/01/20/how-european-cannabis-seed-companies-are-quietly-taking-over-the-us-market/">How European Cannabis Seed Companies Are Quietly Taking Over The U.S. Market</a></li>
<li><a href="https://www.forbes.com/sites/javierhasse/2025/01/19/worlds-largest-tobacco-company-continues-silent-entry-into-cannabis-is-philip-morris-a-medical-marijuana-supporter/">World's Largest Tobacco Company Continues Silent Entry Into Cannabis: Is Philip Morris A Medical Marijuana Supporter?</a></li>
<li><a href="https://www.benzinga.com/news/global/25/01/43181165/raw-founder-celebrates-87m-legal-victory-in-a-very-peculiar-way-we-rolled-it-up-and-smoked-the-lawsuit-literally">RAW Founder Celebrates $8.7M Legal Victory In A Very Peculiar Way: &#8216;We Rolled It Up And Smoked The Lawsuit, Literally&#8217;</a></li>
<li><a href="https://www.benzinga.com/markets/cannabis/25/01/43165973/the-dea-ruling-was-a-game-changer-why-this-european-cannabis-giant-is-betting-on-the-american-seeds-market">&#8216;The DEA Ruling Was A Game-Changer&#8217;: Why This European Cannabis Giant Is Betting On The American Seeds Market</a></li>
<li><a href="https://www.benzinga.com/markets/cannabis/25/01/42033610/whoopi-goldberg-talks-cannabis-the-planets-greatest-medicine-pain-reliever-and-source-of-joy">Whoopi Goldberg Talks Cannabis: The Planet&#8217;s &#8216;Greatest Medicine&#8230; Pain Reliever And Source Of Joy&#8217;</a></li>
<li><a href="https://www.benzinga.com/general/health-care/25/01/43111246/legal-marijuana-linked-to-drop-in-anxiety-medications-what-it-means-for-pharma-giants">Legal Marijuana Linked To Drop In Anxiety Medications: What It Means For Pharma Giants</a></li>
<li><a href="https://www.benzinga.com/general/health-care/25/01/43107039/elizabeth-warren-questions-robert-f-kennedy-jr-on-dangerous-views-pot-legalization-timeline-as-his-senate-hearing-stalls">Elizabeth Warren Questions Robert F. Kennedy Jr. On &#8216;Dangerous Views,&#8217; Pot Legalization Timeline As His Senate Hearing Stalls</a></li>
</ul>

GTBIF

ISPR

The Week In Cannabis: Trump's DEA Pick, Tyson's Reform Push, Dutch Coffee Shop Crisis And More

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed up 22.50% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed up 14.81% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed up 11.75% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/CARA">Cara Therapeutics</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) shares closed up 8.68% at $4.65</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed up 8.61% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed up 6.79% at $0.15</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed up 6.67% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/BLOZF">Cannabix Technologies</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLOZF#OTC">BLOZF</a>) shares closed up 5.19% at $0.27</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed up 5.00% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/GTBIF">Green Thumb Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) shares closed up 3.63% at $7.43</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/AUSAF">Australis Capital</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AUSAF#OTC">AUSAF</a>) shares closed down 50.00% at $0.0001</li>
<li><a href="https://www.benzinga.com/quote/FUAPF">Global Compliance</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUAPF#OTC">FUAPF</a>) shares closed down 34.55% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/XXII">22nd Century Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed down 18.74% at $5.10</li>
<li><a href="https://www.benzinga.com/quote/ITHUF">iAnthus Capital Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed down 17.31% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Glb Inv</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed down 13.98% at $0.29</li>
<li><a href="https://www.benzinga.com/quote/YCBD">cbdMD</a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) shares closed down 10.38% at $0.50</li>
<li><a href="https://www.benzinga.com/quote/CRBP">Corbus Pharmaceuticals</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed down 9.15% at $11.92</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed down 7.20% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/GNLN">Greenlane Hldgs</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares closed down 6.83% at $1.50</li>
<li><a href="https://www.benzinga.com/quote/LVRLF">CordovaCann</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LVRLF#OTC">LVRLF</a>) shares closed down 6.52% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/EAST">Eastside Distilling</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EAST#NASDAQ">EAST</a>) shares closed down 5.54% at $0.73</li>
<li><a href="https://www.benzinga.com/quote/CVSI">CV Sciences</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTC">CVSI</a>) shares closed down 4.02% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/BMMJ">Body and Mind</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BMMJ#OTC">BMMJ</a>) shares closed down 3.77% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed down 3.57% at $2.22</li>
<li><a href="https://www.benzinga.com/quote/CBWTF">Auxly Cannabis Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) shares closed down 3.32% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Gwth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed down 3.11% at $2.18</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AUSAF

BBRRF

BLOZF

BMMJ

CARA

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CRBP

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

CVSI

EAST

FFNTF

FUAPF

GNLN

KAYS

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

LVRLF

NWVCF

OILFF

RMHB

SOLCF

TGIFF

XXII

YCBD

Bearish Sentiment Across The Cannabis Space - Check Full Movers For January 20, 2025

AAWH

ALEAFIA HEALTH INC ORD by Aleafia Health Inc.

ALEAF

AVTBF

AYRWF

BHHKF

CANN

CBDY

CBMJ

CHOOF

CLSH

CLVR

CNBS

CNBX

CNGGF

CNPOF

CNTMF

CNVCF

CPHRF

CRLBF

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

CVHIF

CWBHF

CANNIBIS GROWTH OPTY CORP by Cannabis Growth Opportunity Corp.

CWWBF

CXXIF

ELLXF

EMOR

ETST

EVIO

FFLWF

FUTURE FARM TECHNOLOGIES by Future Farm Technologies Inc.

FFRMF

FLGC

FLOOF

FLWPF

FINCANNA CAPITAL CORP by Fincanna Capital Corp.

FNNZF

GABRIELLAS KITCHEN INC by Gabriella's Kitchen Inc.

GABLF

GBHPF

GENE

GHBWF

GLASF

GRAMF

GRNH

GREEN SPIRIT INDUSTRIES by Green Spirit Industries Inc.

GSRX

FDA Solicits Public Comments On Use Of Cannabis-derived Products In Veterinary Medicine

Comments

Canopy Gwth

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga